Intelerad Medical Systems announced the formation of a new Clinical Decision Support (CDS) Group. The Toronto-based group is made up of developers who will focus on adding evidence-based decision support and data mining features to Intelerad’s solution portfolio.

The Society of Nuclear Medicine and Molecular Imaging’s 2013 Annual Meeting marks the unveiling of the successful application of a new preclinical hybrid molecular imaging system—single photon emission tomography and magnetic resonance (SPECT/MR)—which has exceptional molecular imaging capabilities in terms of potential preclinical and clinical applications, technological advancement at a lower cost, and reduction of patient exposure to ionizing radiation.

For patients with advanced breast cancer, positron emission tomography (PET) and magnetic resonance (MR) imaging can improve quality of life and survival by providing physicians with information on the effectiveness of chemotherapy prior to surgery, say researchers presenting at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging.

HIMSS Analytics recognizes six Legacy Health hospitals, and their ambulatory clinics, located in Portland, Ore. and Vancouver, Wash., with the HIMSS Stage 7 Award, and Stage 7 EMR Ambulatory Award.

 

Laurel Bridge Software's Navigator enterprise medical image fetcher, Navigator allows medical professionals to automate priors fetching, consolidate worklists, monitor unlimited MWLs or HL7 feeds, and support unlimited DICOM sources and destinations.

The Medical Image Workflow Manager is an event-driven workflow manager for the enterprise. The Medical Image Workflow Manager allows physicians to monitor and automate the transfer of images, records, priors, etc., based on HL7 messages, worklist events, time, or other events.

For more information: www.laurelbridge.com

 

Biopharmaceuticals Inc. announced results from two separate studies that compared the performance of Lymphoseek (technetium Tc 99m tilmanocept) Injection, a novel receptor-targeted small-molecule radiopharmaceutical recently approved by the U.S. Food and Drug Administration, with that of radiolabeled sulfur colloid in breast cancer patients undergoing diagnostic evaluation in lymphatic mapping procedures. The studies were presented in oral presentations at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in Vancouver, Canada.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now